Literature DB >> 14972559

The human immunodeficiency virus Vpr protein binds Cdc25C: implications for G2 arrest.

Wei Chun Goh1, Nicolas Manel, Michael Emerman.   

Abstract

The human immunodeficiency virus (HIV) encodes a gene product, Vpr, which causes infected cells to arrest or delay in the G2 phase of the cell cycle. The arrest in G2 is characterized by low levels of Cyclin B1-p34Cdc2 activity and corresponding inhibitory phosphorylation of p34Cdc2. We find that Vpr directly inhibits the in vitro activity of a phosphatase, Cdc25C, which normally activates Cyclin B1-p34Cdc2. Vpr binds to Cdc25C both in vitro and in mammalian cells. Vpr is also able to inhibit Cdc25C phosphatase activity in vitro although it binds to a site on Cdc25C that is distinct from the catalytic site of the enzyme. Expression of both a catalytically active mutant of Cdc25C that has reduced binding to Vpr as well as a catalytically inactive mutant of Cdc25C that retains binding to Vpr is able to largely overcome Vpr-mediated G2 arrest. Finally, depletion of Cdc25C from cells also renders them partially resistant to the effects of Vpr.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972559     DOI: 10.1016/j.virol.2003.10.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  HIV-1 Vpr protein activates the NF-κB pathway to promote G2/M cell cycle arrest.

Authors:  Zhibin Liang; Ruikang Liu; Yongquan Lin; Chen Liang; Juan Tan; Wentao Qiao
Journal:  Virol Sin       Date:  2015-12-14       Impact factor: 4.327

2.  Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway.

Authors:  Naoto Yoshizuka; Yuko Yoshizuka-Chadani; Vyjayanthi Krishnan; Steven L Zeichner
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.

Authors:  Jinwoo Ahn; Thomas Vu; Zach Novince; Jennifer Guerrero-Santoro; Vesna Rapic-Otrin; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

4.  Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle.

Authors:  Kasia Hrecka; Magdalena Gierszewska; Smita Srivastava; Lukasz Kozaczkiewicz; Selene K Swanson; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 11.205

Review 5.  Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.

Authors:  Jason L Dehart; Vicente Planelles
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 6.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

7.  Minute Virus of Mice Inhibits Transcription of the Cyclin B1 Gene during Infection.

Authors:  Matthew S Fuller; Kinjal Majumder; David J Pintel
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

Authors:  Erik S Zimmerman; Junjie Chen; Joshua L Andersen; Orly Ardon; Jason L Dehart; Jana Blackett; Shailesh K Choudhary; David Camerini; Paul Nghiem; Vicente Planelles
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  Cell cycle G2/M arrest through an S phase-dependent mechanism by HIV-1 viral protein R.

Authors:  Ge Li; Hyeon U Park; Dong Liang; Richard Y Zhao
Journal:  Retrovirology       Date:  2010-07-07       Impact factor: 4.602

10.  Human immunodeficiency virus type 1 Vpr induces cell cycle G2 arrest through Srk1/MK2-mediated phosphorylation of Cdc25.

Authors:  Sylvain Huard; Robert T Elder; Dong Liang; Ge Li; Richard Y Zhao
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.